Details for Patent: 11,633,396
✉ Email this page to a colleague
Which drugs does patent 11,633,396 protect, and when does it expire?
Patent 11,633,396 protects LYNPARZA and is included in one NDA.
This patent has fifty-two patent family members in forty-two countries.
Summary for Patent: 11,633,396
| Title: | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
| Abstract: | The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug. |
| Inventor(s): | Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz |
| Assignee: | Kudos Pharmaceuticals Ltd |
| Application Number: | US17/821,833 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,633,396 |
|
Patent Claim Types: see list of patent claims | Composition; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 11,633,396
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-001 | Aug 17, 2017 | RX | Yes | No | 11,633,396 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-002 | Aug 17, 2017 | RX | Yes | Yes | 11,633,396 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,633,396
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2346495 | ⤷ Start Trial | 300956 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2346495 | ⤷ Start Trial | 122018000124 | Germany | ⤷ Start Trial |
| European Patent Office | 2346495 | ⤷ Start Trial | CA 2018 00039 | Denmark | ⤷ Start Trial |
| European Patent Office | 2346495 | ⤷ Start Trial | PA2018014 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
